Management

William B. Stilley, MBA
CEO

Mr. Stilley has over two decades of experience as a life science entrepreneur and executive. Before founding Adovate, he served as CEO of Adial Pharmaceuticals, which he founded and took public.

Other notable roles include VP, Business Development & Strategic Projects at Clinical Data, Inc. (acquired by Forest Laboratories), Chief Business Officer at Diffusion Pharmaceuticals (Nasdaq: DFSN), and COO/CFO at Adenosine Therapeutics. Mr. Stilley has been engaged in all aspects of drug discovery and development including licensing and M&A transactions, management of clinical trials, and production of and manufacturing for multiple drug candidates. He has been a Guest Lecturer at the UVA’s Darden School of Business and serves as an Advisory Board Member for Virginia BIO, as well as Director of Adial Pharmaceuticals, Inc. (Nasdaq) and Avalon GloboCare Corp. He received an MBA with honors from UVA’s Darden School of Business, and a Bachelor of Science in Marketing from the UVA McIntire School of Commerce.
Read More
Joel Linden, PhD
CSO

Dr. Linden has been at the forefront of adenosine research and breakthroughs for over 40 years at the University of Virginia and the La Jolla Institute for Immunology.

His UVA laboratory was the first to study cardiac and vascular adenosine receptors by developing novel radioligands and characterizing adenosine receptor expression, regulation, and signaling. His contribution earned him the Established Investigator Award from the American Heart Association. To date, he has 34 issued US patents, published over 300 papers and been cited over 30,000 times (top 2% world-wide). His discoveries in immuno-modulatory effects of adenosine receptors were the basis for Adenosine Therapeutics, founded in 1999 and sold to Forest Laboratories in 2008. His research continues to be pivotal across a number of indications with global market opportunities. Dr. Linden earned a Bachelor of Science in Applied Mathematics and Biology from Brown University, and a PhD in Pharmacology from the University of Virginia.
Read More
Uday Gupta, MBA
CFO

Mr. Gupta is an experienced entrepreneur and executive with over a 20-year record of accomplishments commercializing novel innovations in many segments across healthcare.

Prior experience includes launching products in drug discovery/regenerative medicine, functional food ingredients and medical devices. Based on award-winning products, he was selected one of 40 Under 40 Profiles by the Medical Device and Diagnostic Industry. He also spent time in a Fortune 100 company where he delivered critical financial results by leading the launch and oversight of new solutions. He earned a Bachelor of Science in Biology at VCU, and an MBA from UVA’s Darden School of Business.
Read More
John R. Martin, JD
CLO

Mr. Martin is a successful attorney and entrepreneur and has 25+ years of legal experience working with companies ranging from Fortune 100 companies to launching or growing technology focused start-ups.

In this role, he provides strategic business and legal advice and services on an enterprise-wide basis, including general corporate commercial and employment law, public and private financings, mergers and acquisitions, and other sophisticated business transactions. He often fills the role of general counsel, aiding with general contract drafting and negotiation, licenses, master service agreements, and board meetings. He is an active angel investor as well as member of local non-for-profits supporting entrepreneurial activities and technology innovations. John is currently a member of the California and Virginia bars. During law school, Mr. Martin served as an Executive Editor of the University of California Law Review.
Read More
Schuyler Vinzant
VP, Pharmaceutical Development

Mr. Vinzant has over 25 years of clinical and regulatory development experience with a primary focus on increasing value for emerging pharmaceutical and biotech companies.

He is an expert at advancing lead drug candidates into the clinic across a broad range of indications in small molecule, gene therapy, and engineered cell therapies. Relevant to Adovate, he has specific expertise in asthma, pain, several cancer indications, ADHD, wounds and orphan product development and has contributed the development of several approved products including Alvesco® (asthma), Herceptin® (cancer), Zydelig® (cancer), VYJUVEK™ (wounds), and Vyvanse® (ADHD).
Read More
Robert D. Thompson, PhD
VP, Chemistry

Dr. Thompson has over 35 years of experience in medicinal chemistry focused primarily on synthesizing adenosine analogs. He is acknowledged as a world leader in adenosine chemistry and is an inventor on over twenty issued patents.

Dr. Thompson has directed medicinal chemistry programs of biotechnology companies including Adenosine Therapeutics, PGX Health (a division of Clinical Data), Forest Laboratories, and Lewis and Clark Pharmaceuticals as well as founder of Purnovate, LLC. He earned a PhD in Organic Chemistry from Brigham Young University and a Bachelor of Science in Chemistry and Math from Southern Utah University.
Read More